PBMCs from T2DM patients treated with saxagliptin, a dipeptiyl peptidase 4 (DPP-4) inhibitor, exhibit reduced levels of IL-23, JAK2, STAT3, and RORγt (81). Here, JAK2 is linked to type 2 diabetes mellitus.